Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01238796 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
A Phase 1 study of End Stage Renal Disease and Kidney Diseases, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 4
- Study locations
NCT01238796: Completed Phase 1 study of End Stage Renal Disease and Kidney Diseases, sponsored by Cumberland Pharmaceuticals.
NCT01238796 is a Phase 1 study of End Stage Renal Disease and Kidney Diseases that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 45 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01238796, a Phase 1 study of End Stage Renal Disease and Kidney Diseases, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of renal function on the biological activity of telavancin using blood samples obtained from subjects with normal renal function, severe renal impairment, and end stage renal disease.
Conditions Studied
Interventions
- DRUG telavancin
Study Locations (4)
Florida
- Clinical Pharmacology of Miami - Miami
- Orlando Clinical Research Center - Orlando
Minnesota
- DaVita Clinical Research - Minneapolis
Tennessee
- New Orleans Center for Clinical Research - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
What the finished NCT01238796 record still lists
NCT01238796 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which telavancin is the first listed.
NCT01238796 reports a single indexed study location in Florida, Minnesota, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01238796 about?
NCT01238796 is a clinical study titled "A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin". The purpose of this study is to evaluate the effect of renal function on the biological activity of telavancin using blood samples obtained from subjects with normal renal function, severe renal impairment, and end stage renal disease.
What is the current status of trial NCT01238796?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2010-12. Estimated completion is 2011-02.
What conditions does trial NCT01238796 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Kidney Diseases.
What interventions are being tested in trial NCT01238796?
The interventions under investigation include: telavancin (DRUG).
Who is sponsoring clinical trial NCT01238796?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01238796 being conducted?
This trial has 4 study locations across Florida, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01238796's enrollment target sits among peer trials
45 54th of 86 higher than 33 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
COMPLETED · Phase 1
-
Plazomicin Study in ESRD Patients Receiving IHD
COMPLETED · Phase 1
-
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia